Research Progress and Safety Evaluation of Immunotherapy for Cancer

As cancer remains a leading cause of death and morbidity worldwide, more effective immunotherapy strategies are urgently needed. Recent advances in immunotherapy, particularly through antibody-drug conjugates (ADCs), therapeutic vaccines, and immune checkpoint inhibitors (ICIs), show promising potential to improve patient outcomes. Still, there is significant debate about the long-term safety and effectiveness of these therapies, which are intended for different patient populations. This article analyzes recent studies of three different immunotherapies, adc, therapeutic vaccines, and ICIs, and makes the point that although these therapies improve survival and quality of life for many patients, there are still inconsistencies in treatment response and safety. The results emphasize the significance of tailored treatment strategies based on tumor biology and unique patient features. This study is significant because it adds to the expanding field of cancer treatment by offering some guidance on how to best use immunotherapy techniques. However, issues such as treatment resistance and individual differences in response to different patients remain unresolved. Future research will focus on this area, particularly in identifying biomarkers for better patient stratification and improved combination therapy approaches.